Predictive biomarkers for inflammatory bowel disease-associated dysplasia

Recruiting

• Conditions: Cancer; Dysplasia; 10017969; 10017991

• Registration Number: NL-OMON51848
• Lead Sponsor: Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 2000

Inclusion Criteria

All adult patients (>=18 y/o) with a diagnosis of IBD undergoing surveillance
colonoscopies can be enrolled after giving written informed consent to
enrollment.

Exclusion Criteria

- Ongoing malignancy (other than CRC).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Identification of mucosal immune populations and the microbiome in biopsies<br /><br>taken from patients with aIBD with and without dysplasia, and with and without<br /><br>colitis-associated cancer. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Determination of patients* genotype (including whole genome methylome and<br /><br>transcriptome) associated with mucosal immunotype and microbiome in<br /><br>relationship to the presence of dysplasia/cancer.<br /><br><br /><br>Determination of luminal microbiome (in biopsies and faeces) associated with<br /><br>mucosal immunotype and microbiome in relationship to the presence of<br /><br>dysplasia/cancer<br /><br><br /><br>Determination of serum cytokines and chemokines associated with mucosal<br /><br>immunotype and microbiome in relationship to the presence of dysplasia/cancer</p><br>